Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue at Rs 2,959 crore; grew by 8% YoY. Gross Margin: 75.3%, Op. EBITDA margin at 32.6%. Op. EBITDA at Rs 964 crore, up by 9% YoY. Net Profit after tax at Rs 498 crore, up by 11% YoY. R&D; Spend was Rs 150 crore (5.1%) vs Rs 139 crore (5.1%) — up 8% YoY FY25 Financial Highlights: Revenue reached Rs 11,516 crore vs Rs 10,728 crore — up 7% YoY Gross Profit grew to Rs 8,740 crore (75.9%) from Rs 8,042 crore (75.0%) — up 9% YoY Operating EBITDA increased to Rs 3,721 crore (32.3%) from Rs 3,368 crore (31.4%) — up 10% YoY PAT (adjusted) came in at Rs 1,911 crore (16.6%) vs Rs 1,656 crore (15.4%) — up 15% YoY R&D; Spend rose to Rs 581 crore (5.0%) vs Rs 527 crore (4.9%) — up 10% YoY Result PDF
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY25 results Revenue at Rs 2,809 crore grew by 3% Gross Margin: 76.0%, Op. EBITDA margin at 32.5%. Op. EBITDA at Rs 914 crore, up by 5%. Net Profit after tax at Rs 503 crore, up by 14% No insulin CMO sales in the quarter. Dispatches restarted from January 2025. During the quarter, BRL depreciated by 17% YoY. Underlying revenue growth adjusted for above transient impact is 7% and Operating EBITDA growth is 12% Result PDF